US20180084819A1 - A method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying - Google Patents
A method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying Download PDFInfo
- Publication number
- US20180084819A1 US20180084819A1 US15/564,632 US201615564632A US2018084819A1 US 20180084819 A1 US20180084819 A1 US 20180084819A1 US 201615564632 A US201615564632 A US 201615564632A US 2018084819 A1 US2018084819 A1 US 2018084819A1
- Authority
- US
- United States
- Prior art keywords
- protein
- spray
- active agent
- divalent metal
- spray dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 139
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 139
- 239000011859 microparticle Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000001694 spray drying Methods 0.000 title claims abstract description 44
- 239000011159 matrix material Substances 0.000 title claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 56
- 239000002253 acid Substances 0.000 claims abstract description 52
- 239000013543 active substance Substances 0.000 claims abstract description 45
- 229910052751 metal Inorganic materials 0.000 claims abstract description 38
- 239000002184 metal Substances 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims abstract description 14
- 235000013365 dairy product Nutrition 0.000 claims abstract description 14
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 8
- 239000007921 spray Substances 0.000 claims description 34
- 239000000416 hydrocolloid Substances 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000000835 fiber Substances 0.000 claims description 8
- 235000020971 citrus fruits Nutrition 0.000 claims description 7
- 241000207199 Citrus Species 0.000 claims description 6
- SWAHNYZETRJYMT-UHFFFAOYSA-L calcium;2-hydroxy-2-methylbutanoate Chemical compound [Ca+2].CCC(C)(O)C([O-])=O.CCC(C)(O)C([O-])=O SWAHNYZETRJYMT-UHFFFAOYSA-L 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 132
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 67
- 239000006185 dispersion Substances 0.000 description 50
- 239000000203 mixture Substances 0.000 description 48
- 239000000243 solution Substances 0.000 description 47
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 36
- 239000002245 particle Substances 0.000 description 34
- 238000001035 drying Methods 0.000 description 30
- 229960005070 ascorbic acid Drugs 0.000 description 28
- 239000011575 calcium Substances 0.000 description 28
- 239000011668 ascorbic acid Substances 0.000 description 27
- 235000010323 ascorbic acid Nutrition 0.000 description 27
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 26
- 229910052791 calcium Inorganic materials 0.000 description 24
- 239000007788 liquid Substances 0.000 description 24
- 239000000463 material Substances 0.000 description 23
- 230000002776 aggregation Effects 0.000 description 21
- 238000004132 cross linking Methods 0.000 description 21
- 108010046377 Whey Proteins Proteins 0.000 description 20
- 238000000889 atomisation Methods 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- 238000004220 aggregation Methods 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 18
- 230000000975 bioactive effect Effects 0.000 description 18
- 235000001465 calcium Nutrition 0.000 description 18
- 238000009826 distribution Methods 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- 229960005137 succinic acid Drugs 0.000 description 17
- 239000001384 succinic acid Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- 235000021119 whey protein Nutrition 0.000 description 15
- 159000000007 calcium salts Chemical class 0.000 description 14
- 102000007544 Whey Proteins Human genes 0.000 description 13
- 229910000019 calcium carbonate Inorganic materials 0.000 description 13
- 239000008267 milk Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 12
- 229940107187 fructooligosaccharide Drugs 0.000 description 12
- 230000007935 neutral effect Effects 0.000 description 12
- 108010084695 Pea Proteins Proteins 0.000 description 11
- 150000001768 cations Chemical class 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- 235000019702 pea protein Nutrition 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 102000011632 Caseins Human genes 0.000 description 9
- 108010076119 Caseins Proteins 0.000 description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 239000003431 cross linking reagent Substances 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000020183 skimmed milk Nutrition 0.000 description 9
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 8
- 239000005018 casein Substances 0.000 description 8
- 235000021240 caseins Nutrition 0.000 description 8
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 150000001450 anions Chemical class 0.000 description 7
- 239000011325 microbead Substances 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- 108010011756 Milk Proteins Proteins 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 229940091250 magnesium supplement Drugs 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000002572 peristaltic effect Effects 0.000 description 6
- 238000011020 pilot scale process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 239000005905 Hydrolysed protein Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102000014171 Milk Proteins Human genes 0.000 description 5
- 229940076638 ascorbic acid and calcium Drugs 0.000 description 5
- -1 calcium Chemical class 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000009969 flowable effect Effects 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 235000020191 long-life milk Nutrition 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000020477 pH reduction Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000004845 protein aggregation Effects 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011692 calcium ascorbate Substances 0.000 description 3
- 235000010376 calcium ascorbate Nutrition 0.000 description 3
- 229940047036 calcium ascorbate Drugs 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000012527 feed solution Substances 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000011833 salt mixture Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-NUNKFHFFSA-N 2-dehydro-L-idonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-NUNKFHFFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000235858 Acetobacter xylinum Species 0.000 description 1
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- VBUYCZFBVCCYFD-UHFFFAOYSA-N D-arabino-2-Hexulosonic acid Natural products OCC(O)C(O)C(O)C(=O)C(O)=O VBUYCZFBVCCYFD-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001027846 Homo sapiens Protein FAM53B Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001635574 Sabatia angularis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000002805 Triticum turgidum Species 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- GQXSDDHYUVYJCQ-NHRVJRKFSA-N [(3as,4as,8ar,8bs)-2,2,7,7-tetramethyl-4a,5,8a,8b-tetrahydro-[1,3]dioxolo[3,4]furo[1,3-d][1,3]dioxin-3a-yl]methanol Chemical compound O([C@H]12)C(C)(C)OC[C@@H]1O[C@]1(CO)[C@H]2OC(C)(C)O1 GQXSDDHYUVYJCQ-NHRVJRKFSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- ZFAVADMJZHASIM-UHFFFAOYSA-N hydroxymethyl butanoate Chemical compound CCCC(=O)OCO ZFAVADMJZHASIM-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LDZBPVVIVSRUGI-UHFFFAOYSA-J tetracalcium chloride phosphate Chemical compound P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Cl-].[Ca+2] LDZBPVVIVSRUGI-UHFFFAOYSA-J 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/10—Whey; Whey preparations containing inorganic additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/08—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/003—Particle size control by passing the aerosol trough sieves or filters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
- C08J3/122—Pulverisation by spraying
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
- H01M10/00—Secondary cells; Manufacture thereof
- H01M10/42—Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
- H02J7/34—Parallel operation in networks using both storage and other dc sources, e.g. providing buffering
- H02J7/345—Parallel operation in networks using both storage and other dc sources, e.g. providing buffering using capacitors as storage or buffering devices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/228—Gelling agent
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
- A23V2250/282—Oligosaccharides, digestible
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5036—Carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/506—Guar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
- H01M10/00—Secondary cells; Manufacture thereof
- H01M10/05—Accumulators with non-aqueous electrolyte
- H01M10/052—Li-accumulators
- H01M10/0525—Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries
Definitions
- the invention relates to method of producing microparticles by spray drying, especially microparticles of the type having a crosslinked and aggregated protein matrix in which the protein is of dairy or vegetable origin.
- Examples of such encapsulation methods include emulsification, fluidized-bed coating, laminar jet breakup, coacervation, liposomes, complexation, crystallization and spray-drying. Most of these methods require the disintegration of a liquid, which can be done by a large number of techniques such as pressure atomization by pressure nozzles or two-fluid gas-stream atomization usually with air or steam as the atomising fluid.
- Laminar jet breakup i.e. production of micro-particles
- spray-drying i.e. atomization by rotating disc
- these types of microparticles are produced by providing a suspension of denatured protein, for example whey protein, and an active agent, treating the suspension to provide microdroplets using a vibrating nozzle, and then immediately immersing the microdroplets in an acidification bath to gel and solidify the microdroplets.
- this method produces spherical, homogenously-sized microdroplets that are capable of gastric transit intact, the process involves use of specialised vibrating nozzle machinery which represents an additional expense for food companies.
- specialised vibrating nozzle machinery which represents an additional expense for food companies.
- spray dryers See FIG. 1 schematic.
- this technology also requires a pre-heating step for the preparation of denatured protein.
- microbeads generated by the technology WO2010119041 is not easily achieved using spray drying technology since the relatively large size of the micro-beads causes a disruption of the atomisation processes.
- micro-beads In order to avoid deposits of wet and sticky micro-beads on the drier wall (See FIG. 2 ), micro-beads must be completely dry before they make contact with the interior wall of the drying chamber. Hence, micro-bead trajectories must be kept away from the drying chamber wall for longest time possible to allow correct drying; however this is not practically possible for commercial spray-drying scenarios.
- Spray drying is a suspended particle dryer technique consisting of three essential steps: i) atomization, where the droplets are formed; ii) drying gas and droplet contact, where the liquid feed is turned into droplets; and finally iii) powder recovery, where the dried particles are separated from the drying gas stream.
- a spray dryer to produce microparticles for bioactive stabilisation would involve re-designing of the micro-bead production process (WO2010119041), as it is not possible or appropriate to employ an acidification bath with spray dried particles, as the particles are dehydrated and atomised in the drying chamber.
- a principal objective in drying involves the assurance that the liquid comes to disc speed and to obtain a uniform drop size distribution in the atomised liquid.
- the readjustment of shear stresses within the liquid once the droplet is airborne is another factor contributing to further disintegration of the droplet/microparticle.
- This is again a limitation for microbead technologies using spray-drying.
- spray drying is generally more flexible, more efficient and more economical in terms of installation, investment and operation for the same evaporative capacity. For instance, the evaporative capacity of a normal sized pharmaceutical spray dryer can match the evaporative capacity of 5-7 large freeze dryers.
- US2014/348815 discloses a method of producing microparticles by spray-drying that employs sodium alginate as a polymer for making the microparticle matrix, and employs a feedstock comprising a volatile base such as ammonia hydroxide or other volatile amines such as hydrazines, methylamine, trimethylamine, or ethylamine.
- a volatile base such as ammonia hydroxide or other volatile amines such as hydrazines, methylamine, trimethylamine, or ethylamine.
- alginate is such a strong gelling agent
- only very low amounts can be employed in spray-drying feedstock which means that the total solids of the resultant microparticles is quite low, resulting in less polymerisation of the matrix and consequently a weaker and less stable matrtix, reduced yield of active agent (cargo) during drying, and less control of particle size.
- the Applicant has overcome the problems set out above by providing a liquid feedstock solution comprising protein, acid, and a crosslinking agent in an inactive precursor form that is activated in the elevated temperature conditions of the drying chamber to release a divalent metal crosslinking agent which crosslinks and aggregates the protein at the atomised droplet stage.
- the precursor crosslinking agent is a volatile divalent metal salt that is insoluble in the feedstock and which dissociates at elevated dryer temperatures to release the divalent metal ion which is an active crosslinking agent.
- the feedstock includes a weak acid which maintains the pH of the feedstock above the pH at which the volatile divalent metal salt solubilises, and obviates the need for a volatile base.
- dairy or vegetable protein as a matrix forming agent (as opposed to alginate) allows the formulation of spray-drying feedstocks with greater total solids content, and consequently greater levels of matrix polymerisation with resultant improvement in microparticle stability and yield.
- the use of the method of the invention allows the production of microparticles having am active agent yield of 50% to more than 80% of the microparticle (w/w), which is a significant improvement compared to the methods of the prior art which achieve about 11%-13% yield of active (cargo).
- the invention provides a method of producing microparticles by spray drying, the method comprising the steps of:
- the feedstock comprises a hydrocolloid. This allows for the formation of a matrix protein-hydrocolloid polymerised cross-linked matrix which has been demonstrated to provide a stronger matrix and consequent improved stability of the active agent.
- the invention also provides a liquid feedstock suitable for spray-drying and comprising water, a volatile divalent metal salt, weak acid, protein (for example 5-15% w/v), and active agent (for example 1-20% w/v), the feed solution having a pH at which the volatile divalent metal salt is substantially insoluble.
- the amount of weak acid, salt and protein can be varied but generally 5-15% protein (w/v) is employed, and the concentration of weak acid and salt can be adjusted to ensure that the salt is insoluble in the feedstock suspension and that there is sufficient salt to cause crosslinking and aggregation of the protein in the atomised droplet in the drying chamber.
- a 0.2 to 2.2M aqueous weak acid solution is employed in the feedstock.
- a 0.1 to 2.0M suspension of volatile divalent metal salt is employed in the feedstock.
- the pH is acidic and typically a salt is employed that is insoluble at acidic pH.
- the pH of the feedstock solution is at least 6. In one embodiment, the pH of the feedstock solution is at least 7. In one embodiment, the pH of the feedstock solution is at least 8. In one embodiment, the pH of the feedstock solution is from 5 to 8. In one embodiment, the pH of the feedstock solution is from 6 to 8. In one embodiment, the pH of the feedstock solution is about 7.
- the volatile divalent metal salt comprises a divalent metal ion selected from calcium, zinc or magnesium. In one embodiment, the volatile divalent metal salt comprises a volatile anion selected from chloride, phosphate, carbonate, citrate, ascorbate or mixtures thereof. Mixtures of various calcium sources are commonly found in infant formula applications. In one embodiment, the volatile divalent metal salt comprises a plurality of different salts, for example a calcium salt plus a magnesium salt, or a calcium carbonate plus a calcium chloride. In one embodiment, the volatile divalent metal salt comprises a mixture of calcium carbonate, calcium triphosphate, and calcium chloride.
- the weak acid is selected from ascorbic acid, acetic acid or succinic acid.
- the weak acid comprises a mixture of weak acids, for example acetic acid plus ascorbic acid, or ascorbic acid plus succinic acid.
- the protein is selected from dairy protein (i.e. whey or casein), egg protein, vegetable protein or mixtures thereof.
- the dairy protein is selected from casein, or whey protein.
- Sources of casein include UHT milk and skim milk powder.
- Sources of whey protein include Whey Protein Isolate (WPI).
- the vegetable protein is selected from pea protein, rice protein or wheat protein (gluten).
- the feedstock dispersion has a solids content of 30-70%, preferably 40-60%, more preferably 45-55%, and ideally approximately 50%.
- the spray-drying feedstock solution is prepared by the sequential steps of:
- the aqueous solution of weak acid has a weak acid concentration of 0.2 M-2.2 M (2%-20%).
- the volatile divalent metal salt has a volatile divalent metal salt concentration of 0.1 M-2.0 M (1%-20%).
- the aqueous dispersion of protein has a protein concentration of 4-15% (w/v).
- the active agent/protein dispersion and weak acid/volatile divalent metal salt solution are mixed at a ratio of 1.0:1.5 to 1.5:1.0 to form the spray-drying feed solution.
- the feedstock solution comprises hydrocolloid.
- some of the protein is replaced by hydrocolloid. This has been found to improve capsule strength and help prevent or inhibit moisture migration into the microparticles, due to hydrocolloid induced increases in polymerisation.
- the use of hydrocolloids in the feedstock allows for a higher solids content in the drier, which delivers a more efficient commercial production and enhanced commercial production yield.
- the feedstock may comprise 10% protein and 5% hydrocolloid.
- the feedstock solution comprises 0.1 to 10.0% hydrocolloid (w/v), preferably 1-7% (w/v), and ideally 1-5% (w/v).
- the hydrocolloid is selected from FOS, GOS, inulin, carrageenan and guar gum.
- the invention also provides a spray-dried microparticle having an active agent homogenously dispersed throughout a continuous protein matrix, in which the protein matrix comprises agglomerated and divalent metal ion crosslinked protein.
- the microparticle comprises hydrocolloid.
- the hydrocolloid is selected from FOS, GOS, inulin, carrageenan and guar gum.
- the microparticle has a dimension of less than 100 microns, for example 29-90 microns.
- the microparticle comprises at least 50%, 60%, 70% or 80% active agent (w/w). In one embodiment, the microparticle comprises at least 50% active agent (w/w), in which the active agent is a cell. In one embodiment, the microparticle comprises at least 70%, active agent (w/w) in which the active agent is non-cellular, for example a compound.
- the protein comprises dairy protein, vegetable protein, or a mixture of dairy protein and vegetable protein.
- the spray-dried microparticle of the invention is capable of surviving gastric transit in a mammal in an intact form.
- the mammal is a human. See FIG. 13 .
- the feedstock (or the microparticle) does not comprise a hydrophobic compound.
- Microparticle means a particle having an average dimension of 10-250 microns as determined by electron microscopy or standard size distribution analysis having a protein matrix crosslinked and aggregated by divalent metal ions. Typically the microparticles has a monodispersed matrix, which means that the components of the microparticle are homogenously mixed in a single phase. This is distinct and different from microcapsules having a core-shell morphology.
- the microparticle has an average dimension of 10-80 microns. In one embodiment, the microparticle has an average dimension of 10-60 microns. In one embodiment, the microparticle has an average dimension of about 20 to about 50 microns.
- Food grade as applied to a spray-drying feedstock or microparticle means that all the components in the feedstock or microparticle are food grade, i.e. suitable for oral ingestion by humans.
- Spray drying is a quintessential preservation and encapsulation method for active agents, such as peptides, micronutrients, starter cultures, probiotics and biological cells lines with poor viability characteristics.
- Most spray dryers consist of feed pump, atomizer, air heater, air disperser, drying chamber, and systems for exhaust air cleaning and powder recovery ( FIG. 1 ).
- “Feedstock solution” or “Liquid feedstock” means the liquid mixture of components that are fed to the atomiser in the spray dryer. Some of the components will be soluble and some insoluble and homogenously dispersed. It generally comprises water, protein, weak acid and volatile divalent metal salt in an insoluble dispersed form. The water and weak acid may be combined into an aqueous solution of weak acid.
- the first step in the spray drying process of the invention is to prepare the feedstock for spraying by optimizing the temperature, concentration, viscosity or other characteristics.
- the method of preparing the feedstock comprises preparation of a weak acid/salt dispersion, preparation of a protein/active agent solution/dispersion, and mixture of the acid/salt dispersion with the protein/active solution or dispersion.
- Rotary atomization can be defined as a disintegrating system where the feed liquid is distributed centrally on a wheel, disc or cup, and centrifugally accelerated to a high velocity before being discharged as droplets into the surrounding air-gas atmosphere.
- Solids content means the percent of the feedstock that is composed of solids. Most feedstock has approx. 50% solids, although the range is from about 15% to 70%. Increasing the solids content reduces the amount of moisture removed in the spray drying process. As the solids content increases, the feedstock becomes more difficult to pump and atomize.
- Volatile divalent metal salt means a salt formed between a divalent metal cation, typically a food grade cation such as calcium, and a volatile anion such as a carbonate.
- volatile anion means an anion forming part of a salt that vaporises at spray drying chamber temperatures, for example a temperature of greater than 80° C., for example 80-190° C.
- volatile divalent metal salts include calcium chloride tricalcium phosphate (commonly known as CTP), calcium citrate, calcium ascorbate, calcium carbonate, calcium HMB (hydroxymethyl butyrate), magnesium phosphate, magnesium carbonate, magnesium citrate, magnesium ascorbate, magnesium HMB, zinc phosphate, zinc carbonate, gluconate; lactate, glycerophosphate, divalent metal HMB, and mixture thereof (See Table 1).
- Zinc compounds have higher astringency values and a glutamate-like sensation; and bitterness is known to be pronounced for magnesium and calcium salts. Bitterness was affected by the anion in calcium salts.
- the feedstock solution having a pH at which the volatile divalent metal salt is substantially insoluble should be understood to mean a pH at which the salt is in a dispersed, non-solubilised, form. Most volatile divalent metal salts are insoluble at acidic pH, therefore the pH of the feedstock is generally acidic. However, in some embodiments, for example when calcium triphosphate is employed, the pH of the feedstock may be lower than 7, for example above 5.
- Viscosity means the resistance to flow of fluids. The most commonly used unit is the centipoise. Increasing viscosity tends to increase droplet size. For some nozzle designs, increasing the viscosity tends to increase the flow rate.
- Strong acid means an acid that dissociates incompletely, releasing only some of its hydrogen atoms into the solution. Hence, it is less capable than a strong acid of donating protons. These acids have higher pKa than strong acids, which release all of their hydrogen atoms when dissolved in water.
- Protein means a dairy protein (i.e. casein or whey) or diary protein preparation (SMP or WPI) or a vegetable protein (pea) or vegetable protein preparation, or mixtures thereof.
- the protein comprises a mixture of a dairy protein and vegetable protein.
- the protein may be provided intact (non-hydrolysed) or partially or fully hydrolysed form.
- “Intact protein” in this context is interpreted as non-hydrolysed protein. This means that the protein bonds in the intact protein fraction should be intact, i.e. a degree of hydrolysis (DH) of 0%.
- the Degree of Hydrolysis (DH) may be determined using a rapid OPA test (Nielsen, P. M.; Petersen, D.; Dambmann, C. Improved method for determining food protein degree of hydrolysis. Journal of Food Science 2001, 66, 642-646).
- the invention therefore relates to a composition as described above wherein the delivery vehicle comprises between 1% or 100% intact protein as a fraction of the total protein content of the particles.
- Active agent should be understood to encompass any molecule, compound, complex, organelle, or cell, in any form, that would benefit from being protected within a protein matrix. Typically, the active agent confers a beneficial effect or pharmacological activity upon interaction with any cell, tissue or organ of a mammal.
- the active agent can compromise of probiotic cells, bacteria, yeasts, enzymes, colours, vitamins, minerals, flavours, hydrophobic peptides, vaccines (mycoplasma) and mixtures thereof.
- Examples of active agents include cells (i.e. probiotic cells or stem cells), compounds (i.e. vitamins or minerals), complexes (HDAC inhibitors) proteins or peptide (i.e. insulin, VEGF), antibodies (i.e.
- the active agent is a cell.
- the active agent is a vitamin (for example, a water soluble vitamin such as Vitamin C).
- the active agent is a cell, and comprises 1-20% of the feedstock (w/v).
- the active agent is a compound, and the active agent comprises 1-60% of the feedstock (w/v).
- the active agent is a compound, and the active agent comprises 10-50% of the feedstock (w/v).
- the active agent is a compound, and the active agent comprises 30-50% of the feedstock (w/v).
- Ka means the acid dissociation constant, K a , (also known as acidity constant, or acid-ionization constant) is a quantitative measure of the strength of an acid in solution.
- Dairy protein means any protein source isolated from expressed from the mammary glands of a female mammal. Dairy proteins include any of the following:
- “Vegetable protein” means any protein isolated and/or extracted from a herbaceous plant with parts that are typically used as a source of food for mammals. Sources include, soy, pea, rice, hempseed, quinoa, various grains (i.e. wheat) and nut sources.
- Texttured protein means a by-product of extracting soybean oil that is often used as a meat analogue or meat extender.
- Droplet means a subdivision of the feed being sprayed from the atomizer. As long as there is surface moisture in the spray, it is said to be composed of droplets.
- Particle means a subdivision of the dried product. The shape of a particle depends on how the droplet was formed and how it behaved during drying.
- Aggregate means an entity consisting of two or more particles adhering to each other.
- Aggregation is the process whereby 2 or more particles adhere/are attracted to each other.
- Particle Size means the size of a spherical particle expressed as there diameter measurement. For non-spherical particles, the size can be represented as an apparent diameter.
- Particle shape means the process of atomizing and drying produces which in turn generates many particles that are non-spherical in shape.
- a “shape factor” is used to express the divergence of a particle shape from spherical.
- Size distribution relates to the fact that droplets and particles that are produced in a spray dryer are never of one particular size. Any nozzle will produce both large and small droplets.
- the dryer must operate so that it is able to dry the largest droplet without scorching the smallest one. Size distributions can be represented by a cumulative distribution curve.
- Mean values can represent diameter, surface area, length, volume and other parameters.
- “Hydrocolloid” means a colloid system where the colloid particles are hydrophilic polymer dispersed in water that is generally food grade. Examples include alginate, gelatin, carrageenan, pectin, citrus fibre, Beta-glucan, starch, guar gum, gum arabic, cellulose, fructooligosaccharide (FOS), galactooligosaccharides (GOS), and related derivatives (i.e. carboxymethylcellulose), arabinoxylans (i.e. citrus fibres) and mixtures thereof.
- a hydrocolloid is any food grade material, presented in a flowable powder format that can be dispersed and mixed with water.
- FIG. 1 Schematic of a standard Spray drier.
- FIG. 2 Illustration of Mug Ring in a dry chamber.
- FIG. 3 List of divalent salt with potential use in the presented invention.
- FIG. 4 Calibration range for the use of a weak acid and a relevant calcium salt (single sources or mixtures of relevant chloride, carbonate or citrate salts).
- FIG. 5 Size distribution of spray-dried native protein (Skim Milk Protein) showing the small particle size (COMPARATIVE).
- FIG. 6 SEM image of native protein (Skim Milk Protein) spray-dried in the absence of the Acid/base mix (COMPARATIVE).
- FIG. 7 Size distribution of pea protein microparticles spray-dried according to the method of the invention in the presence of a calcium salt mixture (3 different calcium salt sources).
- FIG. 8 SEM images illustrating the pea protein microparticles of the invention of FIG. 7 .
- FIG. 9 Size distribution of microparticles spray dried according to the invention, and which employ two protein sources (Whey Protein Isolate and Pea Protein isolate) and one calcium salt (calcium triphosphate).
- FIG. 10 SEM image illustrating the pea protein/WPI microparticles of the invention of FIG. 9 .
- FIG. 11 Size distribution of microparticles spray dried according to the invention, and which employ one protein source (Whey Protein Isolate) and one calcium salt (calcium carbonate).
- one protein source Whey Protein Isolate
- one calcium salt calcium carbonate
- FIG. 12 SEM image illustrating the WPI microparticles of the invention of FIG. 11 .
- FIG. 13 Survival of a probiotic stain ( Lb. acidophilus ) in the presence of succinic acid and ascorbic acid as the weak acid in the mix. Image of the particulate network after drying with entrapped probiotic cells.
- FIG. 14 Percent insoluble generated in the presence/absence of EDTA
- This invention relates to the making of microparticles in a spray dryer using a liquid feedstock comprising protein and a crosslinking agent in an inactive precursor form.
- the liquid feedstock comprises a crosslinking agent in the form of a volatile divalent metal salt, and a weak acid that maintains the pH of the feedstock prior to atomisation above the pH at which the volatile divalent metal salt solubilises.
- the feedstock typically dispersion remains dispersible, flowable to enable extrusion through a nozzle or rotating disk.
- no cross-linking or protein aggregation occurs before atomisation in the drying chamber due to sequential addition of native protein, a weak acid and a salt of a volatile base.
- the volatile divalent metal salt comprises a divalent metal cation (i.e.
- the affinity of calcium ions for the protein is a higher attractive force relative the weak acid present.
- the formation of a calcium ascorbate or calcium acetate is not a likely occurrence due to the high availability of protein aggregates and the significantly lower concentration of weak acid.
- the calcium will always be attracted and available for protein aggregation, crosslinking and polymerisation.
- the use of a mixture of calcium salts sources i.e. calcium triphosphate, calcium chloride, calcium carbonate can provide for a better and enhanced aggregation reaction.
- two different protein sources are admixed prior to spray drying i.e. milk protein+pea protein or whey protein+sodium casein, the result is polymerisation of the proteins in the presence of divalent cations with the formation of ionic and disulfide links.
- the present invention illustrates a crosslinking and agglomeration reaction between a protein and a divalent salt for the stabilisation of bioactive compounds with efficient atomisation characteristics for the generation of a flowable, stable, wettable and commercial powders suitable for a platform of food and therapeutic applications.
- the presented invention illustrates that the protein matrix material and crosslinking agent must be i) combined and introduced to the drying chamber as as single liquid feedstock.
- the feedstock dispersion must remain soluble, flowable and suitable for extrusion through a nozzle or rotating disk.
- No cross-linking agglomeration reaction is should occur before atomisation in the drying chamber i.e. divalent ions must not be available for interaction.
- a volatile base and weak acid are introduced sequentially into the feedstock in order to maintain a flowable dispersion.
- high heat conditions will catalyse the evaporation of the volatile base, leading to a significant pH reduction and concomitant release of (crosslinking) divalent cations, which will be present in a bioavailable, soluble form.
- the bioavailability of divalent cations will spontaneously activate the aggregation of protein molecules; the latter of which are hydrolysed as a result of high heat in the drying chamber.
- the release of cross-linking ions and the availability of partially hydrolysed protein provides optimum conditions for a protein crosslinking and subsequent aggregation in the drying chamber.
- Hydrocolloid or protein i.e. UHT milk, skim milk powder SMP, soy, milk or vegetable protein, FOS, GOS, carrageenan, alginate or hydrocolloid mixtures thereof
- Divalent salt i.e. Calcium, Magnesium, zinc, or mixtures thereof
- Weak Acid i.e. ascorbic acid, succinic acid, acetic acid, or mixtures thereof
- Succinic acid (IUPAC name is butanedioic acid is a diprotic, dicarboxylic acid with chemical formula C 4 H 6 O 4 and structural formula HOOC—(CH 2 ) 2 —COOH. It is a white, odourless solid. Succinate plays a role in the citric acid cycle, an energy-yielding process. Succinic acid is used in the food and beverage industry, primarily as an acidity regulator. It is also sold as a food additive and dietary supplement, and is generally recognized as safe for those uses by the U.S. Food and Drug Administration. As an excipient in pharmaceutical products it is used to control acidity and, more rarely, in effervescent tablets.
- succinic acid occurs naturally in foods, there is no evidence that it is hazardous to man or animals. Moreover, experimental animals tolerate succinic acid in amounts equivalent to several g per kg of body weight. By contrast, a reasonable average daily intake of succinic acid added to foods is estimated to be less than 0.01 mg per day, a dosage that is orders of magnitude less than that required to elicit toxic signs in experimental animals. Based on these considerations, the Select Committee concludes that: There is no evidence in the available information on succinic acid that demonstrates, or suggests reasonable ground to suspect, a hazard to the public when it is used at levels that are now current or that might reasonably be expected in the future.
- Ascorbic acid is a six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. It is a white to slightly yellow crystalline powder that gradually darkens on exposure to light. Solubility in water is approx. 80% at 100 Deg C. and 40% at 45 Deg C. Manufacture: The classical Reichstein-Grussner synthesis starts with reduction of D-glucose to D-sorbitol by hydrogenation over a nickel catalyst.
- the microbiological oxidation of D-sorbitol to L-sorbose is carried out with Acetobacter xylinum .
- Acetobacter xylinum On treatment of L-sorbose with acetone at low temperature in the presence of sulfuric acid, 2,3:4,6-di-O-isopropylidene-alpha-L-sorbofuranose is formed.
- the di-O-isopropylidenyl protection of the hydroxyl-groups at C-2, C-3 and C-4, C-6 allows high-yield oxidation to di-O-isopropylidene-2-ketogulonic acid, without over-oxidation or other side reactions.
- the oxidation is carried out with potassium permanganate in alkaline solution.
- Vitamin C (Ascorbic Acid) in Vitamin Preparations and Juices.
- 2,4-Dichloroindophenol Titrimetric Method Ascorbic acid reduces oxidation-reduction indicator dye, 2,4-dichloroindophenol, to colorless solution. At end point, excess unreduced dye is rose pink in acid solution.
- Vitamin is extracted and titration is performed in presence of HPO3-HOAc or HPO3-HOAc—H2SO4 solution to maintain proper acidity for reaction and to avoid autoxidation of ascorbic acid at high pH. (Reference: Association of Official Analytical Chemists. Official Methods of Analysis. 15 th ed. and Supplements. Washington, D.C.: Association of Analytical Chemists, 1990, p. 1059).
- ascorbic acid concentrations are optimum to permit the natural and adequate neutral pH for the feedstock i.e. neutral pH to avoid maintain divalent ions in an ‘Unavailable state”.
- Formulation optimisation of a weak acid and the salt of a volatile base system where the salt is insoluble at neutral pH values Ascorbic acid and calcium carbonate were screened at various concentration as illustrated in FIG. 4 . Aliquots of 0.2M of the calcium salt was added to ascorbic acid to determine the appropriate concentration to make an feasible mix for drying.
- FIG. 5 illustrates the size distribution a native protein source, after a spray drying process.
- the size distribution is relatively low i.e. 12.2 microns ⁇ 1.53 microns with a narrow size distribution. This illustrates the expected size range that a native protein would generate after heat processing through a spray drier.
- Microscopy illustrated no change in the particle size of native protein ( FIG. 6 ) where the average particle size is expected to be 12.5 microns.
- FIG. 7 illustrates the size distribution of the mix when the calcium is sourced from several salts i.e. chloride, carbonate, phosphate.
- the size distribution is significantly greater than native protein after drying; which endorses the aggregation of protein particles, as evidenced in FIG. 6 .
- Scanning Electron Microscope images illustrate a change in particle morphology as a result of drying in the presence of a calcium salt mixture.
- FIG. 8 the presence is aggregated protein is shown with a large particle size. Individual aggregated particulates are 103 microns ⁇ 1.5 microns with a narrow distribution for individual protein particles. This illustrates a stable drying process and efficient atomisation process.
- FIGS. 9 and 10 The use of two protein sources and once calcium source further illustrates the aggregation process ( FIGS. 9 and 10 ) with the generation of aggregates with diameters of approx. 56.34 microns. SEM endorses the completion of the protein aggregation reaction. Most importantly the use of i) one/two protein sources and ii) a single/cocktail of calcium salt source will dictate the final particle size of the dried powder. This final particle size will be further dictate the production application for the ingredient. FIGS. 10 and 11 further illustrate the aggregation reaction when one protein and one calcium salt is utilised. Particles are generated with a narrow size distribution i.e. 63.6 microns ⁇ 1.9 microns with specific product applications.
- the particle remain below 10 microns in diameter which further provides for a stable dispersion of the powder in aqueous solutions.
- the particles a stable dispersion of soluble aggregates for the protection of a specific entrapped bioactive.
- the type of weak acid utilised has no significant impact upon the survival of specific bioactives.
- FIG. 12 illustrates that the use of succinic acid or ascorbic acid has not effect on the viability of probiotic bacteria during the drying process.
- the pH of the final product will dictate the type of weak acid to be utilised.
- EDTA is utilised to bind the protein and sedimentation reactions are also performed. EDTA was utilised in this experiment in order to verify if the calcium was in a bound or free state.
- the assay was performed as follows:
Abstract
A method of producing microparticles by spray drying comprises the steps of providing a spray-drying feedstock solution comprising water, a volatile divalent metal salt, weak acid, 5-15% dairy or vegetable protein (w/v) and 1-20% active agent (w/v). The feedstock solution is adjusted to have a pH at which the volatile divalent metal salt is substantially insoluble. The feedstock solution is then spray-dried at an elevated temperature to provide atomised droplets, whereby the volatile divalent metal salt disassociates at the elevated temperature to release divalent metal ions which crosslink and aggregate the protein in the atomised droplets to produce micro-particles having a crosslinked aggregated protein matrix and active agent dispersed throughout the matrix.
Description
- The invention relates to method of producing microparticles by spray drying, especially microparticles of the type having a crosslinked and aggregated protein matrix in which the protein is of dairy or vegetable origin.
- The disintegration of liquid into small droplets have long been a significant field of research interest, due to two reasons: (1) to apply to a liquid in some unit operations (particularly drying, cooling or freezing) and 2) to produce granular/capsular materials that offer some advantages such as stability, ease of dosing/handling and specific processing surface characteristics. This disintegration of liquid into droplets is evident in the field of micro-encapsulation where a core material (i.e. bioactive) is inserted or entrapped in a matrix (for example, WO2010119041) for improved bioactive protection, product yield and also to facilitate subsequent production processes. Examples of such encapsulation methods include emulsification, fluidized-bed coating, laminar jet breakup, coacervation, liposomes, complexation, crystallization and spray-drying. Most of these methods require the disintegration of a liquid, which can be done by a large number of techniques such as pressure atomization by pressure nozzles or two-fluid gas-stream atomization usually with air or steam as the atomising fluid.
- Laminar jet breakup (i.e. production of micro-particles) and spray-drying (i.e. atomization by rotating disc) both remain the most promising processing technologies for the food and feed industry since conditions are mild, there is no significant problem of blockages/plugging and the processes are continuous and commercially viable. For example, methods of producing microparticles (using laminar jet breakup) having dairy protein matrices are well known and described in, for example, WO2010119041 (Teagasc). Generally, these types of microparticles are produced by providing a suspension of denatured protein, for example whey protein, and an active agent, treating the suspension to provide microdroplets using a vibrating nozzle, and then immediately immersing the microdroplets in an acidification bath to gel and solidify the microdroplets. While this method produces spherical, homogenously-sized microdroplets that are capable of gastric transit intact, the process involves use of specialised vibrating nozzle machinery which represents an additional expense for food companies. There is therefore a desire amongst food/feed producers and especially milk producers for a method of producing such microparticles using conventional food processing machinery such as spray dryers (See
FIG. 1 schematic). Furthermore, this technology also requires a pre-heating step for the preparation of denatured protein. This pre-denaturation step can indeed be incorporated into industrial operations for value-added products; however, manufacturers of commodity/lower value products continue to seek practical and direct routes for the stabilisation of lower market value materials. Furthermore, the drying of microbeads generated by the technology WO2010119041 is not easily achieved using spray drying technology since the relatively large size of the micro-beads causes a disruption of the atomisation processes. In order to avoid deposits of wet and sticky micro-beads on the drier wall (SeeFIG. 2 ), micro-beads must be completely dry before they make contact with the interior wall of the drying chamber. Hence, micro-bead trajectories must be kept away from the drying chamber wall for longest time possible to allow correct drying; however this is not practically possible for commercial spray-drying scenarios. - Spray drying is a suspended particle dryer technique consisting of three essential steps: i) atomization, where the droplets are formed; ii) drying gas and droplet contact, where the liquid feed is turned into droplets; and finally iii) powder recovery, where the dried particles are separated from the drying gas stream. The use of a spray dryer to produce microparticles for bioactive stabilisation would involve re-designing of the micro-bead production process (WO2010119041), as it is not possible or appropriate to employ an acidification bath with spray dried particles, as the particles are dehydrated and atomised in the drying chamber.
- A principal objective in drying involves the assurance that the liquid comes to disc speed and to obtain a uniform drop size distribution in the atomised liquid. However, the readjustment of shear stresses within the liquid once the droplet is airborne is another factor contributing to further disintegration of the droplet/microparticle. This is again a limitation for microbead technologies using spray-drying. To date, there is almost no records or publication on the area required for the collection of cross-linked & aggregated particles from the rotating disc in good conditions. In comparison to lyophilisation, spray drying is generally more flexible, more efficient and more economical in terms of installation, investment and operation for the same evaporative capacity. For instance, the evaporative capacity of a normal sized pharmaceutical spray dryer can match the evaporative capacity of 5-7 large freeze dryers. In many cases, however, the two technologies are supplementary. For small batches of difficult-to-dry powders to be supplied in vials, lyophilisation has an advantage, whereas spray drying has an advantage if free flowing powders are required. For this reason, the stabilisation of bioactive material using spray drying is a field with huge interest.
- To summarise, spray-drying of protein feedstock solutions produces very small particles, too small to be able to entrap active agents such as probiotic cells (See
FIGS. 5 and 6 ). One possible solution to this problem is replacement of an atomiser nozzle in a spray dryer with a vibrating nozzle, however this approach resulted in large droplets that stuck to the dryer wall (FIG. 2 ). A further possible solution is to add a cross-linking agent to the liquid feedstock with a view to making larger spray-dried particles that consist of cross-linked protein, however this results in cross-linking of the protein in the feedstock liquid prior to atomisation, with a resultant increase in viscosity and in most cases gelation of the feedstock liquid making it impossible to atomise the feedstock solution. - US2014/348815 discloses a method of producing microparticles by spray-drying that employs sodium alginate as a polymer for making the microparticle matrix, and employs a feedstock comprising a volatile base such as ammonia hydroxide or other volatile amines such as hydrazines, methylamine, trimethylamine, or ethylamine. The use of such volatile bases would prevent the microparticles being classified as food-grade products. Moreover, as alginate is such a strong gelling agent, only very low amounts can be employed in spray-drying feedstock which means that the total solids of the resultant microparticles is quite low, resulting in less polymerisation of the matrix and consequently a weaker and less stable matrtix, reduced yield of active agent (cargo) during drying, and less control of particle size.
- It is an object of the invention to overcome these problems. It is a particular object of the invention to provide a method of producing food grade active-containing microparticles by means of conventional spray-drying that have greater yields that the methods of the prior art.
- The Applicant has overcome the problems set out above by providing a liquid feedstock solution comprising protein, acid, and a crosslinking agent in an inactive precursor form that is activated in the elevated temperature conditions of the drying chamber to release a divalent metal crosslinking agent which crosslinks and aggregates the protein at the atomised droplet stage. The precursor crosslinking agent is a volatile divalent metal salt that is insoluble in the feedstock and which dissociates at elevated dryer temperatures to release the divalent metal ion which is an active crosslinking agent. The feedstock includes a weak acid which maintains the pH of the feedstock above the pH at which the volatile divalent metal salt solubilises, and obviates the need for a volatile base. The use of dairy or vegetable protein as a matrix forming agent (as opposed to alginate) allows the formulation of spray-drying feedstocks with greater total solids content, and consequently greater levels of matrix polymerisation with resultant improvement in microparticle stability and yield. In particular, the use of the method of the invention allows the production of microparticles having am active agent yield of 50% to more than 80% of the microparticle (w/w), which is a significant improvement compared to the methods of the prior art which achieve about 11%-13% yield of active (cargo).
- Thus, in a first aspect, the invention provides a method of producing microparticles by spray drying, the method comprising the steps of:
-
- providing a spray-drying feedstock solution comprising water, a volatile divalent metal salt, weak acid, protein (for example 5-15% w/v), and active agent (for example 1-20% w/v), the feed solution having a pH at which the volatile divalent metal salt is substantially insoluble;
- spray drying the feedstock solution at an elevated temperature to form atomised droplets whereby the volatile divalent metal salt disassociates at the elevated temperature to release divalent metal ions which crosslink and subsequently aggregate the protein in the atomised droplets to produce microparticles having a crosslinked aggregated protein matrix and active agent dispersed throughout the matrix.
- In one embodiment, the feedstock comprises a hydrocolloid. This allows for the formation of a matrix protein-hydrocolloid polymerised cross-linked matrix which has been demonstrated to provide a stronger matrix and consequent improved stability of the active agent.
- The invention also provides a liquid feedstock suitable for spray-drying and comprising water, a volatile divalent metal salt, weak acid, protein (for example 5-15% w/v), and active agent (for example 1-20% w/v), the feed solution having a pH at which the volatile divalent metal salt is substantially insoluble.
- It will be appreciated that the amount of weak acid, salt and protein can be varied but generally 5-15% protein (w/v) is employed, and the concentration of weak acid and salt can be adjusted to ensure that the salt is insoluble in the feedstock suspension and that there is sufficient salt to cause crosslinking and aggregation of the protein in the atomised droplet in the drying chamber. Typically, a 0.2 to 2.2M aqueous weak acid solution is employed in the feedstock. Typically, a 0.1 to 2.0M suspension of volatile divalent metal salt is employed in the feedstock.
- Typically, the pH is acidic and typically a salt is employed that is insoluble at acidic pH. In one embodiment, the pH of the feedstock solution is at least 6. In one embodiment, the pH of the feedstock solution is at least 7. In one embodiment, the pH of the feedstock solution is at least 8. In one embodiment, the pH of the feedstock solution is from 5 to 8. In one embodiment, the pH of the feedstock solution is from 6 to 8. In one embodiment, the pH of the feedstock solution is about 7.
- In one embodiment, the volatile divalent metal salt comprises a divalent metal ion selected from calcium, zinc or magnesium. In one embodiment, the volatile divalent metal salt comprises a volatile anion selected from chloride, phosphate, carbonate, citrate, ascorbate or mixtures thereof. Mixtures of various calcium sources are commonly found in infant formula applications. In one embodiment, the volatile divalent metal salt comprises a plurality of different salts, for example a calcium salt plus a magnesium salt, or a calcium carbonate plus a calcium chloride. In one embodiment, the volatile divalent metal salt comprises a mixture of calcium carbonate, calcium triphosphate, and calcium chloride.
- Preferably, the weak acid is selected from ascorbic acid, acetic acid or succinic acid. In one embodiment, the weak acid comprises a mixture of weak acids, for example acetic acid plus ascorbic acid, or ascorbic acid plus succinic acid.
- Preferably, the protein is selected from dairy protein (i.e. whey or casein), egg protein, vegetable protein or mixtures thereof.
- Preferably, the dairy protein is selected from casein, or whey protein. Sources of casein include UHT milk and skim milk powder. Sources of whey protein include Whey Protein Isolate (WPI).
- Preferably, the vegetable protein is selected from pea protein, rice protein or wheat protein (gluten).
- Preferably, the feedstock dispersion has a solids content of 30-70%, preferably 40-60%, more preferably 45-55%, and ideally approximately 50%.
- Preferably, the spray-drying feedstock solution is prepared by the sequential steps of:
-
- preparing an aqueous solution of weak acid;
- preparing an aqueous dispersion of volatile divalent metal salt;
- mixing the solution and dispersion to provide a weak acid/volatile divalent metal salt dispersion and adjusting the pH such that the volatile divalent metal salt is substantially insoluble;
-
- preparing an aqueous dispersion of protein;
- admixing the active agent with the aqueous dispersion of protein to provide an active agent/protein dispersion; and
- admixing the active agent/protein dispersion and weak acid/volatile divalent metal salt dispersion, typically at a ratio of 1.0:1.5 to 1.5:1.0, to form the spray-drying feedstock solution.
- Preferably, the aqueous solution of weak acid has a weak acid concentration of 0.2 M-2.2 M (2%-20%).
- Preferably, the volatile divalent metal salt has a volatile divalent metal salt concentration of 0.1 M-2.0 M (1%-20%).
- Preferably, the aqueous dispersion of protein has a protein concentration of 4-15% (w/v).
- Preferably, the active agent/protein dispersion and weak acid/volatile divalent metal salt solution are mixed at a ratio of 1.0:1.5 to 1.5:1.0 to form the spray-drying feed solution.
- In one embodiment, the feedstock solution comprises hydrocolloid. Typically, some of the protein is replaced by hydrocolloid. This has been found to improve capsule strength and help prevent or inhibit moisture migration into the microparticles, due to hydrocolloid induced increases in polymerisation. In particular, the use of hydrocolloids in the feedstock allows for a higher solids content in the drier, which delivers a more efficient commercial production and enhanced commercial production yield. Thus, for example, the feedstock may comprise 10% protein and 5% hydrocolloid. Typically, the feedstock solution comprises 0.1 to 10.0% hydrocolloid (w/v), preferably 1-7% (w/v), and ideally 1-5% (w/v). In one embodiment, the hydrocolloid is selected from FOS, GOS, inulin, carrageenan and guar gum.
- The invention also provides a spray-dried microparticle having an active agent homogenously dispersed throughout a continuous protein matrix, in which the protein matrix comprises agglomerated and divalent metal ion crosslinked protein. In one embodiment, the microparticle comprises hydrocolloid. In one embodiment, the hydrocolloid is selected from FOS, GOS, inulin, carrageenan and guar gum. In one embodiment, the microparticle has a dimension of less than 100 microns, for example 29-90 microns.
- In one embodiment, the microparticle comprises at least 50%, 60%, 70% or 80% active agent (w/w). In one embodiment, the microparticle comprises at least 50% active agent (w/w), in which the active agent is a cell. In one embodiment, the microparticle comprises at least 70%, active agent (w/w) in which the active agent is non-cellular, for example a compound. Typically, the protein comprises dairy protein, vegetable protein, or a mixture of dairy protein and vegetable protein.
- Typically, the spray-dried microparticle of the invention is capable of surviving gastric transit in a mammal in an intact form. Preferably the mammal is a human. See
FIG. 13 . - In one embodiment, the feedstock (or the microparticle) does not comprise a hydrophobic compound.
- “Microparticle” means a particle having an average dimension of 10-250 microns as determined by electron microscopy or standard size distribution analysis having a protein matrix crosslinked and aggregated by divalent metal ions. Typically the microparticles has a monodispersed matrix, which means that the components of the microparticle are homogenously mixed in a single phase. This is distinct and different from microcapsules having a core-shell morphology. In one embodiment, the microparticle has an average dimension of 10-80 microns. In one embodiment, the microparticle has an average dimension of 10-60 microns. In one embodiment, the microparticle has an average dimension of about 20 to about 50 microns.
- “Food grade” as applied to a spray-drying feedstock or microparticle means that all the components in the feedstock or microparticle are food grade, i.e. suitable for oral ingestion by humans.
- “Spray drying” is a quintessential preservation and encapsulation method for active agents, such as peptides, micronutrients, starter cultures, probiotics and biological cells lines with poor viability characteristics. Most spray dryers consist of feed pump, atomizer, air heater, air disperser, drying chamber, and systems for exhaust air cleaning and powder recovery (
FIG. 1 ). - “Feedstock solution” or “Liquid feedstock” means the liquid mixture of components that are fed to the atomiser in the spray dryer. Some of the components will be soluble and some insoluble and homogenously dispersed. It generally comprises water, protein, weak acid and volatile divalent metal salt in an insoluble dispersed form. The water and weak acid may be combined into an aqueous solution of weak acid. The first step in the spray drying process of the invention is to prepare the feedstock for spraying by optimizing the temperature, concentration, viscosity or other characteristics. Typically, the method of preparing the feedstock comprises preparation of a weak acid/salt dispersion, preparation of a protein/active agent solution/dispersion, and mixture of the acid/salt dispersion with the protein/active solution or dispersion.
- “Rotary atomization” can be defined as a disintegrating system where the feed liquid is distributed centrally on a wheel, disc or cup, and centrifugally accelerated to a high velocity before being discharged as droplets into the surrounding air-gas atmosphere.
- “Solids content” means the percent of the feedstock that is composed of solids. Most feedstock has approx. 50% solids, although the range is from about 15% to 70%. Increasing the solids content reduces the amount of moisture removed in the spray drying process. As the solids content increases, the feedstock becomes more difficult to pump and atomize.
- “Volatile divalent metal salt” means a salt formed between a divalent metal cation, typically a food grade cation such as calcium, and a volatile anion such as a carbonate. The term “volatile anion” means an anion forming part of a salt that vaporises at spray drying chamber temperatures, for example a temperature of greater than 80° C., for example 80-190° C.
- Examples of volatile divalent metal salts include calcium chloride tricalcium phosphate (commonly known as CTP), calcium citrate, calcium ascorbate, calcium carbonate, calcium HMB (hydroxymethyl butyrate), magnesium phosphate, magnesium carbonate, magnesium citrate, magnesium ascorbate, magnesium HMB, zinc phosphate, zinc carbonate, gluconate; lactate, glycerophosphate, divalent metal HMB, and mixture thereof (See Table 1). Zinc compounds have higher astringency values and a glutamate-like sensation; and bitterness is known to be pronounced for magnesium and calcium salts. Bitterness was affected by the anion in calcium salts.
- “The feedstock solution having a pH at which the volatile divalent metal salt is substantially insoluble” should be understood to mean a pH at which the salt is in a dispersed, non-solubilised, form. Most volatile divalent metal salts are insoluble at acidic pH, therefore the pH of the feedstock is generally acidic. However, in some embodiments, for example when calcium triphosphate is employed, the pH of the feedstock may be lower than 7, for example above 5.
- “Viscosity” means the resistance to flow of fluids. The most commonly used unit is the centipoise. Increasing viscosity tends to increase droplet size. For some nozzle designs, increasing the viscosity tends to increase the flow rate.
- “Weak acid” means an acid that dissociates incompletely, releasing only some of its hydrogen atoms into the solution. Hence, it is less capable than a strong acid of donating protons. These acids have higher pKa than strong acids, which release all of their hydrogen atoms when dissolved in water.
- “Protein” means a dairy protein (i.e. casein or whey) or diary protein preparation (SMP or WPI) or a vegetable protein (pea) or vegetable protein preparation, or mixtures thereof. In a preferred embodiment, the protein comprises a mixture of a dairy protein and vegetable protein. The protein may be provided intact (non-hydrolysed) or partially or fully hydrolysed form.
- “Intact protein” in this context is interpreted as non-hydrolysed protein. This means that the protein bonds in the intact protein fraction should be intact, i.e. a degree of hydrolysis (DH) of 0%. The Degree of Hydrolysis (DH) may be determined using a rapid OPA test (Nielsen, P. M.; Petersen, D.; Dambmann, C. Improved method for determining food protein degree of hydrolysis. Journal of Food Science 2001, 66, 642-646). The invention therefore relates to a composition as described above wherein the delivery vehicle comprises between 1% or 100% intact protein as a fraction of the total protein content of the particles.
- “Active agent” should be understood to encompass any molecule, compound, complex, organelle, or cell, in any form, that would benefit from being protected within a protein matrix. Typically, the active agent confers a beneficial effect or pharmacological activity upon interaction with any cell, tissue or organ of a mammal. The active agent can compromise of probiotic cells, bacteria, yeasts, enzymes, colours, vitamins, minerals, flavours, hydrophobic peptides, vaccines (mycoplasma) and mixtures thereof. Examples of active agents include cells (i.e. probiotic cells or stem cells), compounds (i.e. vitamins or minerals), complexes (HDAC inhibitors) proteins or peptide (i.e. insulin, VEGF), antibodies (i.e. therapeutic antibodies), nucleic acid (i.e. miRNA, siRNA, genes, vectors, plasmids), drugs (protein-based drugs such as Angiogenin). In one embodiment, the active agent is a cell. In one embodiment, the active agent is a vitamin (for example, a water soluble vitamin such as Vitamin C). In one embodiment, the active agent is a cell, and comprises 1-20% of the feedstock (w/v). In one embodiment, the active agent is a compound, and the active agent comprises 1-60% of the feedstock (w/v). In one embodiment, the active agent is a compound, and the active agent comprises 10-50% of the feedstock (w/v). In one embodiment, the active agent is a compound, and the active agent comprises 30-50% of the feedstock (w/v).
- “pKa” means the acid dissociation constant, Ka, (also known as acidity constant, or acid-ionization constant) is a quantitative measure of the strength of an acid in solution.
- “Dairy protein” means any protein source isolated from expressed from the mammary glands of a female mammal. Dairy proteins include any of the following:
-
- Casein is one of two major groups of protein present in milk. The action of rennet on casein during the manufacture of cheese results in the separating of milk into curds and whey. Casein forms the cheese while the whey proteins go into the whey stream. Sodium caseinate is the final end product from this process stream.
- Milk protein concentrate (MPC)—Milk protein concentrates are produced by ultrafiltration (UF) of milk. The product in liquid form is generally referred to as UF milk while the dry form is known as MPC. This product contains unaltered forms of both casein and whey protein. The level of protein, lactose and mineral present vary depending on the degree of protein concentration.
- Nonfat dry milk (NFDM)—Nonfat dry milk or skim milk powder is skim milk with the water removed. The composition of the original skim milk is not altered.
- Skim milk—Milk that has had the fat removed. The dry form of skim milk is known as nonfat dry milk.
- UHT milk is milk treated to pasteurization which involves heating milk to 138° to 150° C. (280° to 302° F.) for one or two seconds to enable a greater shelf-life and/or stability
- Whey protein concentrate/isolate (WPC/WPI)—Whey protein concentrates are produced by ultrafiltration of whey. They can be in liquid or dry form and have a protein content typically ranging from 34 to less than 90%. When the protein concentration exceeds 90% the product is known as a whey protein isolate (WPI).
- “Vegetable protein” means any protein isolated and/or extracted from a herbaceous plant with parts that are typically used as a source of food for mammals. Sources include, soy, pea, rice, hempseed, quinoa, various grains (i.e. wheat) and nut sources.
- “Textured protein” means a by-product of extracting soybean oil that is often used as a meat analogue or meat extender.
- “Droplet” means a subdivision of the feed being sprayed from the atomizer. As long as there is surface moisture in the spray, it is said to be composed of droplets.
- “Particle” means a subdivision of the dried product. The shape of a particle depends on how the droplet was formed and how it behaved during drying.
- “Aggregate” means an entity consisting of two or more particles adhering to each other.
- “Aggregation” is the process whereby 2 or more particles adhere/are attracted to each other.
- “Particle Size” means the size of a spherical particle expressed as there diameter measurement. For non-spherical particles, the size can be represented as an apparent diameter.
- “Particle shape” means the process of atomizing and drying produces which in turn generates many particles that are non-spherical in shape. A “shape factor” is used to express the divergence of a particle shape from spherical.
- “Size distribution” relates to the fact that droplets and particles that are produced in a spray dryer are never of one particular size. Any nozzle will produce both large and small droplets.
- The dryer must operate so that it is able to dry the largest droplet without scorching the smallest one. Size distributions can be represented by a cumulative distribution curve.
- “Mean” or “median size” means a single value most suited to represent the entire distribution. Mean values can represent diameter, surface area, length, volume and other parameters.
- “Hydrocolloid” means a colloid system where the colloid particles are hydrophilic polymer dispersed in water that is generally food grade. Examples include alginate, gelatin, carrageenan, pectin, citrus fibre, Beta-glucan, starch, guar gum, gum arabic, cellulose, fructooligosaccharide (FOS), galactooligosaccharides (GOS), and related derivatives (i.e. carboxymethylcellulose), arabinoxylans (i.e. citrus fibres) and mixtures thereof. A hydrocolloid is any food grade material, presented in a flowable powder format that can be dispersed and mixed with water.
-
FIG. 1 Schematic of a standard Spray drier. -
FIG. 2 . Illustration of Mug Ring in a dry chamber. -
FIG. 3 . List of divalent salt with potential use in the presented invention. -
FIG. 4 . Calibration range for the use of a weak acid and a relevant calcium salt (single sources or mixtures of relevant chloride, carbonate or citrate salts). -
FIG. 5 . Size distribution of spray-dried native protein (Skim Milk Protein) showing the small particle size (COMPARATIVE). -
FIG. 6 . SEM image of native protein (Skim Milk Protein) spray-dried in the absence of the Acid/base mix (COMPARATIVE). -
FIG. 7 . Size distribution of pea protein microparticles spray-dried according to the method of the invention in the presence of a calcium salt mixture (3 different calcium salt sources). -
FIG. 8 . SEM images illustrating the pea protein microparticles of the invention ofFIG. 7 . -
FIG. 9 . Size distribution of microparticles spray dried according to the invention, and which employ two protein sources (Whey Protein Isolate and Pea Protein isolate) and one calcium salt (calcium triphosphate). -
FIG. 10 . SEM image illustrating the pea protein/WPI microparticles of the invention ofFIG. 9 . -
FIG. 11 . Size distribution of microparticles spray dried according to the invention, and which employ one protein source (Whey Protein Isolate) and one calcium salt (calcium carbonate). -
FIG. 12 . SEM image illustrating the WPI microparticles of the invention ofFIG. 11 . -
FIG. 13 . Survival of a probiotic stain (Lb. acidophilus) in the presence of succinic acid and ascorbic acid as the weak acid in the mix. Image of the particulate network after drying with entrapped probiotic cells. -
FIG. 14 . Percent insoluble generated in the presence/absence of EDTA - This invention relates to the making of microparticles in a spray dryer using a liquid feedstock comprising protein and a crosslinking agent in an inactive precursor form. The liquid feedstock comprises a crosslinking agent in the form of a volatile divalent metal salt, and a weak acid that maintains the pH of the feedstock prior to atomisation above the pH at which the volatile divalent metal salt solubilises. The feedstock typically dispersion remains dispersible, flowable to enable extrusion through a nozzle or rotating disk. Generally, no cross-linking or protein aggregation occurs before atomisation in the drying chamber due to sequential addition of native protein, a weak acid and a salt of a volatile base. The volatile divalent metal salt comprises a divalent metal cation (i.e. calcium, zinc, magnesium or potassium) capable of crosslinking and aggregating the protein, and a volatile anion (i.e. chloride, citrate, carbonate, sulfate, gluconate), that is sensitive to high heat. Thus, at relatively basic pH the salt is insoluble in the feedstock dispersion and unavailable to react with the native protein. However, upon heating of the atomised droplets in the drying chamber, four steps spontaneously occur: i) the heat of the drying chamber partially hydrolyses the protein; ii) the salt disassociates releasing and vaporising the volatile base i.e. anions; iii) evaporation of the volatile base reduces the pH of the dispersion; iv) the development of an acidic environment results in the solubilisation (bioavailability) of divalent metal cations iv) the bioavailability of divalent cations activates the crosslinking and subsequent aggregation reaction of partially hydrolysed protein. Without being bound by theory, the affinity of calcium ions for the protein is a higher attractive force relative the weak acid present. Hence the formation of a calcium ascorbate or calcium acetate is not a likely occurrence due to the high availability of protein aggregates and the significantly lower concentration of weak acid. Hence, the calcium will always be attracted and available for protein aggregation, crosslinking and polymerisation.
- The release of the cross-linking agent, the generation of an acidic environment and the availability of partially hydrolysed protein, provides optimum conditions for the crosslinking and aggregation in the drying chamber of a standard spray-drier. Its activation of protein aggregation as a result of calcium availability is a consequence of protein-protein interaction via calcium (divalent cation). This results in disulfide bond formation during the spray drying. The use of a mixture of calcium salts sources i.e. calcium triphosphate, calcium chloride, calcium carbonate, can provide for a better and enhanced aggregation reaction. When two different protein sources are admixed prior to spray drying i.e. milk protein+pea protein or whey protein+sodium casein, the result is polymerisation of the proteins in the presence of divalent cations with the formation of ionic and disulfide links.
- Thus, the present invention illustrates a crosslinking and agglomeration reaction between a protein and a divalent salt for the stabilisation of bioactive compounds with efficient atomisation characteristics for the generation of a flowable, stable, wettable and commercial powders suitable for a platform of food and therapeutic applications. In essence, the presented invention illustrates that the protein matrix material and crosslinking agent must be i) combined and introduced to the drying chamber as as single liquid feedstock. The feedstock dispersion must remain soluble, flowable and suitable for extrusion through a nozzle or rotating disk. No cross-linking agglomeration reaction is should occur before atomisation in the drying chamber i.e. divalent ions must not be available for interaction. For this reason, a volatile base and weak acid are introduced sequentially into the feedstock in order to maintain a flowable dispersion. Upon introduction of the liquid feedstock into the dryer chamber, high heat conditions will catalyse the evaporation of the volatile base, leading to a significant pH reduction and concomitant release of (crosslinking) divalent cations, which will be present in a bioavailable, soluble form. The bioavailability of divalent cations will spontaneously activate the aggregation of protein molecules; the latter of which are hydrolysed as a result of high heat in the drying chamber. Hence, the release of cross-linking ions and the availability of partially hydrolysed protein, provides optimum conditions for a protein crosslinking and subsequent aggregation in the drying chamber.
- Materials Required
- Polymer:
- Hydrocolloid or protein i.e. UHT milk, skim milk powder SMP, soy, milk or vegetable protein, FOS, GOS, carrageenan, alginate or hydrocolloid mixtures thereof
- Salt:
- Divalent salt i.e. Calcium, Magnesium, zinc, or mixtures thereof
- Acid
- Weak Acid i.e. ascorbic acid, succinic acid, acetic acid, or mixtures thereof
- Succinic Acid:
- Succinic acid (IUPAC name is butanedioic acid is a diprotic, dicarboxylic acid with chemical formula C4H6O4 and structural formula HOOC—(CH2)2—COOH. It is a white, odourless solid. Succinate plays a role in the citric acid cycle, an energy-yielding process. Succinic acid is used in the food and beverage industry, primarily as an acidity regulator. It is also sold as a food additive and dietary supplement, and is generally recognized as safe for those uses by the U.S. Food and Drug Administration. As an excipient in pharmaceutical products it is used to control acidity and, more rarely, in effervescent tablets. At the level succinic acid occurs naturally in foods, there is no evidence that it is hazardous to man or animals. Moreover, experimental animals tolerate succinic acid in amounts equivalent to several g per kg of body weight. By contrast, a reasonable average daily intake of succinic acid added to foods is estimated to be less than 0.01 mg per day, a dosage that is orders of magnitude less than that required to elicit toxic signs in experimental animals. Based on these considerations, the Select Committee concludes that: There is no evidence in the available information on succinic acid that demonstrates, or suggests reasonable ground to suspect, a hazard to the public when it is used at levels that are now current or that might reasonably be expected in the future.
- Ascorbic Acid:
- Ascorbic acid is a six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. It is a white to slightly yellow crystalline powder that gradually darkens on exposure to light. Solubility in water is approx. 80% at 100 Deg C. and 40% at 45 Deg C. Manufacture: The classical Reichstein-Grussner synthesis starts with reduction of D-glucose to D-sorbitol by hydrogenation over a nickel catalyst. The microbiological oxidation of D-sorbitol to L-sorbose is carried out with Acetobacter xylinum. On treatment of L-sorbose with acetone at low temperature in the presence of sulfuric acid, 2,3:4,6-di-O-isopropylidene-alpha-L-sorbofuranose is formed. The di-O-isopropylidenyl protection of the hydroxyl-groups at C-2, C-3 and C-4, C-6 allows high-yield oxidation to di-O-isopropylidene-2-ketogulonic acid, without over-oxidation or other side reactions. The oxidation is carried out with potassium permanganate in alkaline solution. Treatment of/di-O-isopropylidene-2-ketogulonic acid/with hot water affords 2-keto-L-gulonic acid, which is converted to L-ascorbic acid by heating in water at 100 deg C. (20% yield) or by esterification and treatment with sodium methoxide in methanol followed by acidification with hydrogen chloride, yielding ca. 70% of/L-ascorbic acid. The overall yield of ascorbic acid from D-glucose is 15-18%.
- Analytical Method for Detection of Ascorbic Acid:
- AOAC Method 967.21. Vitamin C (Ascorbic Acid) in Vitamin Preparations and Juices. 2,4-Dichloroindophenol Titrimetric Method. Ascorbic acid reduces oxidation-reduction indicator dye, 2,4-dichloroindophenol, to colorless solution. At end point, excess unreduced dye is rose pink in acid solution. Vitamin is extracted and titration is performed in presence of HPO3-HOAc or HPO3-HOAc—H2SO4 solution to maintain proper acidity for reaction and to avoid autoxidation of ascorbic acid at high pH. (Reference: Association of Official Analytical Chemists. Official Methods of Analysis. 15th ed. and Supplements. Washington, D.C.: Association of Analytical Chemists, 1990, p. 1059).
- General Methodology
-
- Spray drying of an aqueous dispersion containing a hydrocolloid mixture containing sufficient protein to allow a crosslinking and subsequent aggregation reaction (UHT milk, skim milk powder, vegetable protein, or mixtures thereof).
- A divalent salt (Calcium, Magnesium, zinc) is introduced that is soluble at acidic pH only.
- A weak acid (ascorbic acid, succinic acid or acetic acid) is introduced at a pH (preferably above pH 5, ideally above pH 7) just above the pike with a volatile base (calcium carbonate, calcium chloride, etc.; See
FIG. 4 ). - Under these conditions, the divalent salt is insoluble and ions are not available for cross-linking and aggregation with the protein molecules from the hydrocolloid component of the mixture.
- when a hydrocolloid such as FOS or GOS is employed, the hydrocolloid can be admixed to the weak acid, or added to the liquid feedstock at any point but typically just prior to the preheating stage.
- The solution (liquid feedstock) in this fluid state is preheated and pumped through the nozzle of the single/multi-stage spray drier, where it is effectively atomised.
- Inlet and outlet temperatures are maintained in accordance with standard commercially viable conditions to allow appropriate atomisation. i.e. 180 DegC. inlet and 85-90 Dec outlet temperature
- Upon atomisation at these temperatures the volatile base is vaporised and the protein content enters into a hydrolysed state.
- Upon evaporation of the base, the pH is reduced (hydrogen ions are released into solution) and divalent ions are released and enter a bioavailable state.
- Calcium/the relevant divalent cations is readily available for crosslinking and aggregation with the protein/hydrocolloid source, mixture thereof.
- The crosslinking and subsequent aggregation reaction is initiated as a result of the temperature of the drier. i.e. high temperature permits evaporation of the volatile base, and concomitant hydrolysis of the protein source and bioavailability of the divalent cations. These three conditions accelerate the cross-linking aggregation and entrapment of an active compound.
- Spray drying is the method of choice as it the industry standard for dehydration of materials. Furthermore, it prevents multiplication of contaminants because powders are easy to handle in the field and the method is well documented an accepted across all industrial disciplines.
- Method 1:
-
- Whey protein isolate (WPI) or concentrate (WPC) at a total protein content of 8.0% w/v (protein basis) in water
- The protein dispersion is centrifuged at 10,000 rpm; 16 Dig Celsius; 45 minutes
- Supernatant is agitated overnight at 4° C. at pH 7.5
- The protein dispersion is filtered (0.2 micron) at room temperature
- A solution (8.0% w/v) of ascorbic acid is prepared in water and agitated at room temperature before addition of 2% FOS
- A calcium β-hydroxy-β-methylbutyrate (CaHMB) solution (0.4% (w/v) is prepared and dispersed in water.
- The pH is adjusted to 7.5 using 4M NaOH. This represents a Asc/CaHMB mix.
- The pellet of cells/powdered bioactive material is resuspended in the protein dispersion
- Cell concentrations is approx. 1×1011 CFU/mL.
- Bioactive material can be dispersed at
max 50% solid content. - The protein dispersion with cells/active is then mixed with Ascorbic-Calcium solution at ratio 1:1 (v/v)
- Agitation is then performed at 65° C. to pre-heat for the drier
- At this point the solution is fluid and call the feedstock
- Spray dry the suspension using a single-stage drier
- Standard inlet and outlet temperatures will apply i.e. inlet 180° C. and outlet 85-90° C.
- Delivery of suspension via peristaltic pump was fixed to 600 mL/hr (Bench top) or 20 L per hour (pilot scale).
- Nozzle atomization is utilized as per standard industry practice.
- Material is dried to a Aw of 0.2 and storage at refrigerated temperatures in hermetically sealed drums/foil bags.
- Method 2
-
- Pea protein isolate (PPI) prepared at a total protein content of 9.0% w/v (protein basis) in water
- The protein dispersion is centrifuged at 10,000 rpm; 16 Dig Celsius; 45 minutes
- Supernatant is agitated overnight at 4° C. at pH 7.2
- The protein dispersion is filtered (0.2 micron) at room temperature
- A solution (12.0% w/v) of ascorbic acid is prepared in water and agitated at room temperature before addition of 2% FOS (w/v)
- A calcium carbonate (or calcium ascorbate or calcium citrate or CaHMB) (0.4% (w/v) is prepared and dispersed in water.
- Ascorbic acid and Calcium source is admixed
- At this point, ascorbic acid concentrations are optimum to permit the natural and adequate neutral pH for the feedstock i.e. neutral pH to avoid maintain divalent ions in an ‘Unavailable state”.
- This represents a Asc/Ca mix.
- The pellet of cells/powdered bioactive material is re-suspended in the protein dispersion
- Cell concentrations is approx. 1×1011 CFU/mL.
- Bioactive material can also be dispersed at
max 50% solid content. - The protein dispersion with cells/active is then mixed with Ascorbic-Calcium dispersion at ratio 1:1 (v/v)
- Agitation is then performed at 65° C. to pre-heat for the drier
- At this point the solution is fluid and classified as feedstock
- Spray dry the suspension using a single stage drier
- Standard inlet and outlet temperatures will apply i.e. inlet 180° C. and outlet 85-90° C.
- Delivery of suspension via peristaltic pump was fixed to 600 mL/hr (Bench top) or 20 L per hour (pilot scale).
- Nozzle atomization was used as per standard industry procedure.
- Material is dried to a Aw of 0.2 and storage at refrigerated temperatures in hermetically sealed drums/foil bags.
- Method 3
-
- Pea protein isolate (PPI) or milk protein isolate (WPI) prepared at a total protein content of 9.5% w/v (protein basis) in water
- The protein dispersion is centrifuged at 10,000 rpm; 16° C.; 45 minutes
- Supernatant is agitated overnight at 4° C. at pH 7.5
- The protein dispersion is filtered (0.2 micron) at room temperature
- A solution (12.0% w/v) of ascorbic acid is prepared in water and agitated at room temperature before addition of 2% FOS (w/v)
- A calcium triphosphate, calcium chloride, calcium carbonate solution totally (1.8% (w/v) is prepared and dispersed in water.
- Ascorbic acid and Calcium mix is admixed
- At this point, ascorbic acid concentrations are optimum to permit the natural and adequate neutral pH for the feedstock i.e. neutral pH to avoid maintain divalent ions in an ‘Unavailable state”.
- This represents a Asc/Ca mix.
- The pellet of cells/powdered bioactive material is resuspended in the protein dispersion
- Cell concentrations is approx. 1×1011 CFU/mL.
- Bioactive material can also be dispersed at
max 50% solid content. - The protein dispersion with cells/active is then mixed with Ascorbic-Calcium dispersion at ratio 1:1 (v/v)
- Agitation is then performed at 65° C. to pre-heat for the drier
- At this point the solution is fluid and classified as feedstock
- Spray dry the suspension using a single stage drier
- Standard inlet and outlet temperatures will apply i.e. inlet 180° C. and outlet 85-90° C.
- Delivery of suspension via peristaltic pump was fixed to 600 mL/hr (Bench top) or 20 L per hour (pilot scale).
- Nozzle atomization was used as per standard industry procedure.
- Material is dried to a Aw of 0.2 and storage at refrigerated temperatures in hermetically sealed drums/foil bags.
- Method 4
-
- Whey Protein (WPI/WPC) and pea protein isolate (PPI) prepared at a total protein content of 15.0% w/v (protein basis) in water
- The protein dispersion is centrifuged at 10,000 rpm; 16° C.; 45 minutes
- Supernatant is agitated overnight at 4° C. at pH 7.2
- The protein dispersion is filtered (0.2 micron) at room temperature
- A solution (12.0% w/v) of succinic acid is prepared in water and agitated at room temperature
- A calcium triphosphate (0.5% (w/v) is prepared and dispersed in water.
- Succinic acid and Calcium source is admixed
- At this point, succinic acid concentrations are optimum to permit the natural and adequate neutral pH for the feedstock i.e. neutral pH to avoid maintain divalent ions in an ‘Unavailable state”.
- This represents a Succ/Ca mix.
- The pellet of cells/powdered bioactive material is resuspended in the protein dispersion
- Cell concentrations is approx. 1×1011 CFU/mL.
- Bioactive material can also be dispersed at
max 50% solid content. - The protein dispersion with cells/active is then mixed with Ascorbic-Calcium dispersion at ratio 1:1 (v/v)
- Agitation is then performed at 65° C. to pre-heat for the drier
- At this point the solution is fluid and classified as feedstock
- Spray dry the suspension using a single stage drier
- Standard inlet and outlet temperatures will apply i.e. inlet 180° C. and outlet 85-90° C.
- Delivery of suspension via peristaltic pump was fixed to 600 mL/hr (Bench top) or 20 L per hour (pilot scale).
- Nozzle atomization was used as per standard industry procedure.
- Material is dried to a Aw of 0.2 and storage at refrigerated temperatures in hermetically sealed drums/foil bags
- Method 5:
-
- Whey Protein (WPI/WPC) and pea protein isolate (PPI) prepared at a total protein content of 15.0% w/v (protein basis) in water
- The protein dispersion is centrifuged at 10,000 rpm; 16° C.; 45 minutes
- Supernatant is agitated overnight at 4° C. at pH 7.2
- The protein dispersion is filtered (0.2 micron) at room temperature
- A solution (12.0% w/v) of ascorbic acid is prepared in water and agitated at room temperature
- A calcium triphosphate, calcium chloride, calcium carbonate solution totally (1.8% (w/v) is prepared and dispersed in water.
- Ascorbic acid and Calcium mix is admixed
- At this point, ascorbic acid concentrations are optimum to permit the natural and adequate neutral pH for the feedstock i.e. neutral pH to avoid maintain divalent ions in an ‘Unavailable state”.
- This represents a Asc/Ca mix.
- The pellet of cells/powdered bioactive material is resuspended in the protein dispersion
- Cell concentrations is approx. 1×1011 CFU/mL.
- Bioactive material can also be dispersed at
max 50% solid content. - The protein dispersion with cells/active is then mixed with Ascorbic-Calcium dispersion at ratio 1:1 (v/v)
- Agitation is then performed at 65° C. to pre-heat for the drier
- At this point the solution is fluid and classified as feedstock
- Spray dry the suspension using a single stage drier
- Standard inlet and outlet temperatures will apply i.e. inlet 180° C. and outlet 85-90° C.
- Delivery of suspension via peristaltic pump was fixed to 600 mL/hr (Bench top) or 20 L per hour (pilot scale).
- Nozzle atomization was used as per standard industry procedure.
- Material is dried to a Aw of 0.2 and storage at refrigerated temperatures in hermetically sealed drums/foil bags
- Method 6: Generation of Stable Bioactive Vitamin C
-
- Whey Protein (WPI/WPC) and pea protein isolate (PPI) prepared at a total protein content of 2.0% w/v (protein basis) in water
- The protein dispersion is centrifuged at 10,000 rpm; 16° C.; 45 minutes
- Supernatant is agitated overnight at 4° C. at pH 7.2
- A solution (3.5.0% w/v) of citrus fibre is prepared in water and agitated at room temperature
- Fructo-oligosaccahride (FOS) is prepared at 2.0% (W/v) concentration
- The protein and fibre dispersions are filtered (0.2 micron) at room temperature
- Protein, FOS and citrus fibre is admixed.
- A solution (82.0% w/v) of ascorbic acid is prepared in water and agitated at room temperature
- A calcium triphosphate or calcium chloride solution total 1.8% (w/v) is prepared and dispersed in water.
- Ascorbic acid and Calcium mix is admixed
- At this point, ascorbic acid concentrations are optimum to permit the natural and adequate neutral pH for the feedstock i.e. neutral pH to avoid maintain divalent ions in an ‘Unavailable state”.
-
- The protein, FOS, fibre suspension is then mixed with Ascorbic-Calcium dispersion at ratio 1:1 (v/v)
- Agitation is then performed at 65 Degrees Celsius to pre-heat for the drier
- At this point the solution is fluid and classified as feedstock
- Spray dry the suspension using a single stage drier
- Standard inlet and outlet temperatures will apply i.e. inlet 180 Dec and outlet 85-90 DegC.
- Delivery of suspension via peristaltic pump was fixed to 600 mL/hr (Bench top) or 20 L per hour (pilot scale)
- Nozzle atomization was used as per standard industry pro
- Results:
- Sequential Formulation:
- Formulation optimisation of a weak acid and the salt of a volatile base system where the salt is insoluble at neutral pH values. Ascorbic acid and calcium carbonate were screened at various concentration as illustrated in
FIG. 4 . Aliquots of 0.2M of the calcium salt was added to ascorbic acid to determine the appropriate concentration to make an feasible mix for drying. - It is evident that a minimum quantity of calcium is required to react with the protein content present in the mix. It is also evident that a minimum quantity of weak acid (ascorbic acid is required) to raise the pH to the relevant level above the pKa of the calcium carbonate. Prior to spray drying the optimum ascorbic/succinic acid concentrations of 0.2 M-2.2 M worked well for introduction to calcium carbonate in the range of 0.1 M-2.0 M. Outside these ranges the mixture becomes turbid and there are precise ratios that are required to maintain the appropriate neutral pH, while also having adequate calcium available for crosslinking and aggregation. When the proposed formulation were applied to a spray-drier, the particle size is again significantly change as a result of the hydrolysis of the protein source with concomitant cross-linking and aggregation reaction with the available calcium ions.
- When resultant powders were assessed under Light Microscope, the following changes were observed in contrast to the raw materials. They physiochemical properties of the suspension and related dry powder illustrate the occurrence of the cross-linking reaction between the partially hydrolysed protein and the solubilised Ca2+ ions. The pH of the suspension in a stepwise manner is illustrated as follows:
-
Initial weak Acid/Calcium Salt Mix pH 4.1-5.0 Protein hydrocolloid suspension + Mix (T0) pH 7.0-.7.5 After Spray Drying pH 4.5-5.0 - Determination of Size Distribution
- The presented invention was tested in a standard spray drying process and the effect of the feedstock formulation (protein+weak acid+salt of a volatile base) was investigated as a function of particle size. Firstly, it was important to investigate the effect of spray drying the protein only in the absence of the acid base mixture and
FIG. 5 illustrates the size distribution a native protein source, after a spray drying process. The size distribution is relatively low i.e. 12.2 microns±1.53 microns with a narrow size distribution. This illustrates the expected size range that a native protein would generate after heat processing through a spray drier. Microscopy illustrated no change in the particle size of native protein (FIG. 6 ) where the average particle size is expected to be 12.5 microns. -
FIG. 7 illustrates the size distribution of the mix when the calcium is sourced from several salts i.e. chloride, carbonate, phosphate. The size distribution is significantly greater than native protein after drying; which endorses the aggregation of protein particles, as evidenced inFIG. 6 . Scanning Electron Microscope images illustrate a change in particle morphology as a result of drying in the presence of a calcium salt mixture. InFIG. 8 the presence is aggregated protein is shown with a large particle size. Individual aggregated particulates are 103 microns±1.5 microns with a narrow distribution for individual protein particles. This illustrates a stable drying process and efficient atomisation process. - The use of two protein sources and once calcium source further illustrates the aggregation process (
FIGS. 9 and 10 ) with the generation of aggregates with diameters of approx. 56.34 microns. SEM endorses the completion of the protein aggregation reaction. Most importantly the use of i) one/two protein sources and ii) a single/cocktail of calcium salt source will dictate the final particle size of the dried powder. This final particle size will be further dictate the production application for the ingredient.FIGS. 10 and 11 further illustrate the aggregation reaction when one protein and one calcium salt is utilised. Particles are generated with a narrow size distribution i.e. 63.6 microns±1.9 microns with specific product applications. - The particle remain below 10 microns in diameter which further provides for a stable dispersion of the powder in aqueous solutions. In essence, the particles a stable dispersion of soluble aggregates for the protection of a specific entrapped bioactive.
- The type of weak acid utilised has no significant impact upon the survival of specific bioactives.
-
FIG. 12 illustrates that the use of succinic acid or ascorbic acid has not effect on the viability of probiotic bacteria during the drying process. The pH of the final product will dictate the type of weak acid to be utilised. - The use of calcium as a crosslinking/aggregation agent is further endorsed in
FIG. 13 where - EDTA is utilised to bind the protein and sedimentation reactions are also performed. EDTA was utilised in this experiment in order to verify if the calcium was in a bound or free state. The assay was performed as follows:
-
- Calcium Carbonate was admixed with EDTA in a 2:1 ratio to ensure the excess of EDTA in the reaction mixture
- Adjust the pH to 8.5 and 10 in order to accelerate the binding capacity of EDTA
- Several treatment were prepared as outlined in Table 2
- All samples were Incubated for 24 h at room temperature
- Following incubation, pH values were recorded
- All samples were sedimentation of insolubles were measured
- Insoluble matter was calculated on a percent basis
- It is evident that the spray dried powder with the full reaction mixture generated a higher pelleted material relative the pre-dried mixture. This endorses the fact that the drying process stimulates the aggregation of proteins, which is demonstrated via the presence of higher pellet percent after sedimentation tests i.e. before spray drying the mixture illustrates 9.83% aggregated material; while after spray-drying of the mixture 22.8% sedimentation is generated.
Claims (14)
1-20. (canceled)
21. A spray-dried, food grade, microparticle having an active agent homogenously dispersed throughout a continuous dairy or vegetable protein matrix, in which the protein matrix comprises agglomerated and divalent metal ion crosslinked protein.
22. A spray dried microparticle according to claim 21 and comprising hydrocolloid, in which the active agent is homogenously dispersed throughout a continuous protein-hydrocolloid matrix.
23. A spray dried microparticle according to claim 22 in which the hydrocolloid comprises or consists of FOS.
24. A spray dried microparticle according to claim 22 in which the hydrocolloid comprises or consists of citrus fibre.
25. A spray dried microparticle according to claim 23 in which the hydrocolloid comprises or consists of FOS and citrus fibre, and in which the active agent is homogenously dispersed throughout a continuous protein-FOS-citrus fibre matrix.
26. A spray dried microparticle according to claim 21 having a dimension of 20-90 microns.
27. A spray dried microparticle according to claim 21 in which the active agent is a cell.
28. A spray dried microparticle according to claim 21 in which the active agent is a compound.
29. A spray dried microparticle according to claim 21 and comprising at least 50% active agent (w/w).
30. A spray dried microparticle according to claim 21 and comprising at least 70% active agent (w/w).
31. A spray dried microparticle according to claim 21 and comprising at least 80% active agent (w/w).
32. A spray dried microparticle according to claim 21 and comprising calcium hydroxymethyl butyrate.
33. A spray dried microparticle according to claim 21 , and produced by spray-drying according to a method of:
providing a food-grade spray-drying feedstock solution comprising water, a volatile divalent metal salt, weak acid, 5-15% dairy or vegetable protein (w/v) and active agent (w/v), the feedstock solution having a pH at which the volatile divalent metal salt is substantially insoluble; and
spray drying the feedstock solution at an elevated temperature to provide atomised droplets whereby the volatile divalent metal salt disassociates at the elevated temperature to release divalent metal ions which crosslink and aggregate the protein in the atomised droplets to produce microparticles having a crosslinked aggregated protein matrix and active agent dispersed throughout the matrix.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1508745.5 | 2015-05-21 | ||
GBGB1508745.5A GB201508745D0 (en) | 2015-05-21 | 2015-05-21 | A method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying |
PCT/EP2016/061622 WO2016185053A1 (en) | 2015-05-21 | 2016-05-23 | A method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/061622 A-371-Of-International WO2016185053A1 (en) | 2015-05-21 | 2016-05-23 | A method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/441,841 Continuation US11576416B2 (en) | 2015-05-21 | 2019-06-14 | Method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180084819A1 true US20180084819A1 (en) | 2018-03-29 |
Family
ID=53506147
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,632 Abandoned US20180084819A1 (en) | 2015-05-21 | 2016-05-23 | A method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying |
US16/441,841 Active 2038-09-08 US11576416B2 (en) | 2015-05-21 | 2019-06-14 | Method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/441,841 Active 2038-09-08 US11576416B2 (en) | 2015-05-21 | 2019-06-14 | Method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180084819A1 (en) |
EP (1) | EP3297456B1 (en) |
CN (1) | CN107771036B (en) |
AU (1) | AU2016265469B2 (en) |
CA (1) | CA2981938C (en) |
DK (1) | DK3297456T3 (en) |
GB (1) | GB201508745D0 (en) |
PT (1) | PT3297456T (en) |
SI (1) | SI3297456T1 (en) |
WO (1) | WO2016185053A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10287366B2 (en) | 2017-02-15 | 2019-05-14 | Cp Kelco Aps | Methods of producing activated pectin-containing biomass compositions |
CN111728124A (en) * | 2020-07-08 | 2020-10-02 | 江苏宏远药业有限公司 | Food-grade white pigment with high safety |
US20210106016A1 (en) * | 2019-10-11 | 2021-04-15 | Leprino Foods Company | Tandem evaporation-drying methods and systems for making powdered milk-derived products |
US20210227858A1 (en) * | 2018-11-26 | 2021-07-29 | Purac Biochem B.V. | Particulate food preservative composition |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019170840A1 (en) | 2018-03-07 | 2019-09-12 | Anabio Technologies Ltd. | A composition for type ii diabetics and for use in providing sustained energy release over time |
JP2021528223A (en) * | 2018-06-21 | 2021-10-21 | フイルメニツヒ ソシエテ アノニムFirmenich Sa | Manufacturing method of microcapsules |
CN108912345B (en) * | 2018-06-27 | 2020-06-09 | 江南大学 | Microcapsule wall material based on concentrated lactoprotein and microcapsule |
AU2019394578A1 (en) | 2018-12-03 | 2021-03-18 | Société des Produits Nestlé S.A. | Food or beverage product with agglomerated pea protein |
EP4093211A4 (en) * | 2020-01-24 | 2024-04-03 | Int Flavors & Fragrances Inc | Microencapsulation with plant protein |
WO2021152111A1 (en) | 2020-01-31 | 2021-08-05 | Chr. Hansen A/S | Electrostatic spray drying of microorganisms |
WO2022072193A1 (en) * | 2020-09-30 | 2022-04-07 | Danisco Us Inc | Coated granules produced by in-situ crosslinking process |
CN115212868B (en) * | 2022-08-31 | 2023-08-18 | 四川大学 | Nano metal particle loaded reduced graphene oxide aerogel and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004075662A (en) * | 2002-06-20 | 2004-03-11 | Mukku:Kk | Sustained-release composition, method for producing the same and preparation of the same |
GB2388581A (en) * | 2003-08-22 | 2003-11-19 | Danisco | Coated aqueous beads |
DK2217363T3 (en) * | 2007-11-14 | 2019-01-21 | Univ Queensland | APPLICATION OF A DEVICE AND PROCEDURE FOR MANUFACTURING MICROPARTICLES |
CA2758620C (en) | 2009-04-13 | 2018-10-16 | Agriculture And Food Development Authority (Teagasc) | Method of producing microbeads |
WO2013096883A2 (en) * | 2011-12-23 | 2013-06-27 | The Regents Of The University Of California | Spray dry method for encapsulation of biological moieties and chemicals in polymers cross-linked by multivalent ions for controlled release applications |
US10111835B2 (en) * | 2012-07-05 | 2018-10-30 | Centro Nacional De Tecnología Y Seguridad Alimentaria, Laboratorio Del Ebro | Microparticles for encapsulating probiotics, production and uses thereof |
-
2015
- 2015-05-21 GB GBGB1508745.5A patent/GB201508745D0/en not_active Ceased
-
2016
- 2016-05-23 US US15/564,632 patent/US20180084819A1/en not_active Abandoned
- 2016-05-23 WO PCT/EP2016/061622 patent/WO2016185053A1/en active Application Filing
- 2016-05-23 CA CA2981938A patent/CA2981938C/en active Active
- 2016-05-23 EP EP16729502.1A patent/EP3297456B1/en active Active
- 2016-05-23 SI SI201630577T patent/SI3297456T1/en unknown
- 2016-05-23 CN CN201680029189.4A patent/CN107771036B/en active Active
- 2016-05-23 AU AU2016265469A patent/AU2016265469B2/en active Active
- 2016-05-23 PT PT167295021T patent/PT3297456T/en unknown
- 2016-05-23 DK DK16729502.1T patent/DK3297456T3/en active
-
2019
- 2019-06-14 US US16/441,841 patent/US11576416B2/en active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10287366B2 (en) | 2017-02-15 | 2019-05-14 | Cp Kelco Aps | Methods of producing activated pectin-containing biomass compositions |
US11008407B2 (en) | 2017-02-15 | 2021-05-18 | Cp Kelco Aps | Activated pectin-containing biomass compositions and products |
US20210227858A1 (en) * | 2018-11-26 | 2021-07-29 | Purac Biochem B.V. | Particulate food preservative composition |
US20210106016A1 (en) * | 2019-10-11 | 2021-04-15 | Leprino Foods Company | Tandem evaporation-drying methods and systems for making powdered milk-derived products |
US11832629B2 (en) * | 2019-10-11 | 2023-12-05 | Leprino Foods Company | Tandem evaporation-drying methods and systems for making powdered milk-derived products |
CN111728124A (en) * | 2020-07-08 | 2020-10-02 | 江苏宏远药业有限公司 | Food-grade white pigment with high safety |
Also Published As
Publication number | Publication date |
---|---|
EP3297456A1 (en) | 2018-03-28 |
AU2016265469B2 (en) | 2019-11-14 |
CA2981938A1 (en) | 2016-11-24 |
WO2016185053A1 (en) | 2016-11-24 |
CN107771036B (en) | 2021-04-09 |
CA2981938C (en) | 2023-06-13 |
US20190289896A1 (en) | 2019-09-26 |
AU2016265469A1 (en) | 2017-11-09 |
PT3297456T (en) | 2020-01-17 |
US11576416B2 (en) | 2023-02-14 |
CN107771036A (en) | 2018-03-06 |
EP3297456B1 (en) | 2019-10-09 |
GB201508745D0 (en) | 2015-07-01 |
SI3297456T1 (en) | 2020-03-31 |
DK3297456T3 (en) | 2020-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11576416B2 (en) | Method of producing microparticles of the type having a crosslinked, aggregated protein matrix by spray drying | |
Vaziri et al. | Co-microencapsulation of Lactobacillus plantarum and DHA fatty acid in alginate-pectin-gelatin biocomposites | |
Jain et al. | Characterization of microcapsulated β-carotene formed by complex coacervation using casein and gum tragacanth | |
Pinto et al. | Potential use of whey concentrate and prebiotics as carrier agents to protect Bifidobacterium-BB-12 microencapsulated by spray drying | |
Fávaro-Trindade et al. | The use of spray drying technology to reduce bitter taste of casein hydrolysate | |
Wang et al. | Development of a novel functional drink from all natural ingredients using nanotechnology | |
JP5526033B2 (en) | Fine particle production apparatus and fine particle production method | |
Baracat et al. | Preparation and characterization of microcapsules based on biodegradable polymers: Pectin/casein complex for controlled drug release systems | |
do Amaral et al. | Microencapsulation and Its Uses in Food Science and Technology: A | |
MX2008012334A (en) | Whey protein vehicle for active agent delivery. | |
CN104883900A (en) | Dietary compositions comprising capsules obtained by coacervation without the use of toxic cross-linking agents | |
JP2016527185A (en) | Method for preparing an emulsion of active ingredients and particles obtained from the emulsion | |
Bourbon et al. | Dehydration of protein lactoferrin-glycomacropeptide nanohydrogels | |
JP2021509666A5 (en) | ||
EP2731450B1 (en) | Food-grade encapsulate and process for the production thereof | |
TW201722293A (en) | Composition containing collagen peptide and ceramide, and method for producing same | |
Zhu et al. | Insight into the structural, chemical and surface properties of proteins for the efficient ultrasound assisted co-encapsulation and delivery of micronutrients | |
US20230320398A1 (en) | Stabilized vitamin a and method of production | |
Bleiel et al. | Encapsulation efficiency and capacity of bioactive delivery systems | |
US11224615B2 (en) | Compositions and methods for increasing iron intake in a mammal | |
WO2008077401A1 (en) | Reactive powdering | |
Sarabandi et al. | Spray Drying Encapsulation of Proteins and Bioactive Peptides | |
Wang et al. | Dairy encapsulation systems by atomization-based technology | |
Alvim et al. | Methods of encapsulation | |
Jagdale et al. | Spray drying encapsulation of vitamins and minerals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NUABIOME LIMITED, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANABIO TECHNOLOGIES LIMITED;REEL/FRAME:057410/0466 Effective date: 20210819 |